全球泌尿系统癌症负担趋势:基于2023年全球疾病负担研究的分析
该研究分析1990至2023年全球前列腺癌、膀胱癌、肾癌和睾丸癌的发病、死亡及伤残调整生命年(DALY)变化,分解人口增长、老龄化与年龄别率效应并评估可归因风险。睾丸癌和肾癌年龄标化发病率上升,膀胱癌下降,四种癌症年龄标化死亡率均下降;人口增长和老龄化是病例数增加的主因,可归因风险对膀胱癌和肾癌DALY贡献较大而对前列腺癌贡献很小。
要点
- 1990-2023年睾丸癌和肾癌年龄标化发病率上升,膀胱癌下降,前列腺癌稳定。
- 四种癌症年龄标化死亡率均下降,人口增长与老龄化推高绝对病例数。
核心结论
- 四种泌尿系统癌症的绝对负担增长主要源于人口因素,但不同癌症和地区的轨迹存在差异。
- 睾丸癌在传统老年泌尿系统癌症特征之外增加了年轻成人发病率上升的特点。
- 小规模人群的排名需谨慎解读,预防重点应反映癌症特异性风险模式。
研究设计与样本
- 基于全球疾病负担2023估计,分析前列腺癌、膀胱癌、肾癌和睾丸癌的发病、死亡和DALY。
- 使用估计年度百分比变化总结年龄标化发病率和死亡率,纳入95%不确定性区间。
- 将计数变化分解为人口增长、人口老龄化和年龄别率效应,并评估2021-2023年变化。
主要发现
- 1990-2023年睾丸癌年龄标化发病率估计年度百分比变化为0.98%(95% CI 0.89-1.07),肾癌为0.27%(95% CI 0.13-0.41)。
- 1990-2023年前列腺癌年龄标化发病率稳定,膀胱癌下降,四种癌症年龄标化死亡率均下降。
- 2023年所有建模风险占膀胱癌DALY的34.6%(95% UI 29.7-39.8)和肾癌DALY的27.1%(95% UI 17.0-36.7),仅占前列腺癌DALY的1.6%(95% UI -5.6 to 6.8)。
临床怎么用
- 临床与公共卫生规划需考虑人口增长和老龄化驱动的绝对病例数增加。
- 前列腺癌以外,睾丸癌和肾癌的年龄标化发病率上升提示需关注对应人群的早期识别。
- 膀胱癌和肾癌的较大可归因风险DALY比例支持针对可改变风险因素的预防策略。
- 前列腺癌可归因风险DALY比例很小,提示其预防重点可能不同于其他三种癌症。
- 解读小规模行政区的癌症负担排名时应谨慎,避免因人口阈值导致排名不稳。
局限性
- 原文未报告具体局限性描述。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Our objective was to quantify changes in the global burden of prostate, bladder, kidney and testicular cancers from 1990 to 2023 and to assess demographic contributions and characterize geographic, age-specific and modelled risk-attributable patterns. MATERIALS AND METHODS: We analysed Global Burden of Disease 2023 estimates for incidence, deaths and disability-adjusted life-years (DALYs). Age-standardised incidence rates and death rates were summarised using estimated annual percentage change. We incorporated 95% uncertainty intervals (UIs), decomposed changes in counts into population growth, population ageing and age-specific rate effects, assessed 2021-2023 changes, and repeated country rankings after excluding locations with an implied population <1 million. RESULTS: In 2023, the four cancers accounted for approximately 2.47 million incident cases, 0.88 million deaths and 18.1 million DALYs. Prostate cancer contributed 1.41 million incident cases (95% UI 1.19-1.63 million) and 469 000 deaths (95% UI 413 000-526 000). From 1990 to 2023, age-standardised incidence rates increased for testicular cancer (estimated annual percentage change 0.98%, 95% confidence interval [CI] 0.89-1.07) and kidney cancer (0.27%, 95% CI 0.13-0.41), was stable for prostate cancer, and decreased for bladder cancer; age-standardised death rates decreased for all four cancers. Together, population growth and ageing accounted for the most increases in incident cases, whereas declining age-specific rates offset deaths from prostate, bladder, kidney and testicular cancers. Small-jurisdiction leaders changed materially in the population-threshold sensitivity analysis. In 2023, all modelled risks accounted for 34.6% (95% UI 29.7-39.8) of bladder cancer DALYs and 27.1% (95% UI 17.0-36.7) of kidney cancer DALYs but only 1.6% (95% UI -5.6 to 6.8) of prostate cancer DALYs. CONCLUSION: The growing absolute burden of these cancers was predominantly demographic, but cancer-specific and geographic trajectories differed. Testicular cancer added a young-adult, rising-incidence component to the conventional older-age urological cancer profile. Rankings for small populations require cautious interpretation, and prevention priorities should reflect cancer-specific risk patterns.
引用
- Lu H, Zhang Y, Zhao Y, et al. Global trends in urological cancers: an analysis of the global burden of disease study 2023. BJU Int. 2026. PMID: 42830190. doi:10.1111/bju.70473
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。